Abstract
Nintedanib is an oral angiokinase inhibitor targeting type 1, 2 and 3 VEGF, type α and β PDGF, type 1, 2 and 3FGF receptors, and its action also includes FLT3 and Src group receptors. The drug thus results in altered proliferation and survival of three key cellular populations participating in neoangiogenesis - endothelial cells, pericytes and small muscle cells.
The administered dose is 250mg nintedanib twice daily, in combination with paclitaxel and carboplatin. Currently the first results are available from phase III trials, specifically LUME-Lung 1 trial that observed significantly extended progression-free survival for combination therapy with nintedanib versus placebo, both for the whole patient population and in patients with either adenocarcinoma or squamous cell carcinoma.
The effect of nintedanib on overall survival of the whole patient group was also favourable though not statistically significant.